• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center

Michael S. Rogers, PhD


  • Cryan LM, Bazinet L, Habeshian KA, Cao S, Clardy J, Christensen KA, Rogers MS.1,2,3,4,6-Penta-O-galloyl-β-D-glucopyranose inhibits angiogenesis via inhibition of capillary morphogenesis gene 2.J Med Chem. 2013 Mar 14;56(5):1940-5.
  • Cryan LM, Habeshian KA, Caldwell TP, Morris MT, Ackroyd PC, Christensen KA, Rogers MS.Identification of Small Molecules That Inhibit the Interaction of TEM8 with Anthrax Protective Antigen Using a FRET Assay.J Biomol Screen. 2013 Mar 11.
  • Rogers MS, Adini I, McBride AF, Birsner AE, D'Amato RJ.The albino mutation of tyrosinase alters ocular angiogenic responsiveness.Angiogenesis. 2013 Feb 20.
  • Rogers MS, D'Amato RJ.Common polymorphisms in angiogenesis.Cold Spring Harb Perspect Med. 2012;2(11).
  • Cao S, Cryan L, Habeshian KA, Murillo C, Tamayo-Castillo G, Rogers MS, Clardy J.Phenolic compounds as antiangiogenic CMG2 inhibitors from Costa Rican endophytic fungi.Bioorg Med Chem Lett. 2012 Sep 15;22(18):5885-8.
  • Rogers MS, Cryan LM, Habeshian KA, Bazinet L, Caldwell TP, Ackroyd PC, Christensen KA.A FRET-based high throughput screening assay to identify inhibitors of anthrax protective antigen binding to capillary morphogenesis gene 2 protein.PLoS ONE. 2012;7(6):e39911.
  • Cryan LM, Rogers MS.Targeting the anthrax receptors, TEM-8 and CMG-2, for anti-angiogenic therapy.Front Biosci. 2011;16:1574-88. Review.
  • Nakai K, Rogers MS, Baba T, Funakoshi T, Birsner AE, Luyindula DS, D'Amato RJ.Genetic loci that control the size of laser-induced choroidal neovascularization.FASEB J. 2009 Jul;23(7):2235-43.
  • Rogers MS, Birsner AE, D'Amato RJ.The mouse cornea micropocket angiogenesis assay.Nat Protoc. 2007;2(10):2545-50.
  • Rogers MS, Christensen KA, Birsner AE, Short SM, Wigelsworth DJ, Collier RJ, D'Amato RJ.Mutant anthrax toxin B moiety (protective antigen) inhibits angiogenesis and tumor growth.Cancer Res. 2007 Oct 15;67(20):9980-5.
  • Folkman J, Rogers MS.Thalidomide for multiple myeloma.N Engl J Med. 2006 Jun 1;354(22):2389-90; author reply 2389-90.
  • Rogers MS, D'Amato RJ.The effect of genetic diversity on angiogenesis.Exp Cell Res. 2006 Mar 10;312(5):561-74. Review.
  • Shaked Y, Bertolini F, Man S, Rogers MS, Cervi D, Foutz T, Rawn K, Voskas D, Dumont DJ, Ben-David Y, Lawler J, Henkin J, Huber J, Hicklin DJ, D'Amato RJ, Kerbel RS.Genetic heterogeneity of the vasculogenic phenotype parallels angiogenesis; Implications for cellular surrogate marker analysis of antiangiogenesis.Cancer Cell. 2005 Jan;7(1):101-11.
  • Rogers MS, Rohan RM, Birsner AE, D'Amato RJ.Genetic loci that control the angiogenic response to basic fibroblast growth factor.FASEB J. 2004 Jul;18(10):1050-9.
  • Rogers MS, Rohan RM, Birsner AE, D'Amato RJ.Genetic loci that control vascular endothelial growth factor-induced angiogenesis.FASEB J. 2003 Nov;17(14):2112-4.
  • Browder T, Folkman J, Hahnfeldt P, Heymach J, Hlatky L, Kieran M, Rogers MS.Antiangiogenic therapy and p53.Science. 2002 Jul 26;297(5581):471; discussion 471.
  • Lentzsch S, Rogers MS, LeBlanc R, Birsner AE, Shah JH, Treston AM, Anderson KC, D'Amato RJ.S-3-Amino-phthalimido-glutarimide inhibits angiogenesis and growth of B-cell neoplasias in mice.Cancer Res. 2002 Apr 15;62(8):2300-5.